Drugs / NCR102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06941350 | Apr 2025 → Oct 2026 expected | acute graft versus host disease | Nuwacell Biotechnologies Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-24 | Nuwacell Biotechnologies Co., Ltd. | Results 中盛溯源荣登“2025中国医药创新种子企业100强” nuwacell.com ↗
前期临床研究显示，NCR102对5例儿童和12例成人SR-aGVHD患者的总缓解率（包括完全缓解CR和部分缓解PR）ORR为88.2%，其中完全缓解率CR为76.5%，具有良好的安全性和有效性。 |
| 2025-03-20 | Nuwacell Biotechnologies Co., Ltd. | Regulatory 喜报！中盛溯源第三款iMSC产品获批临床，GVHD治疗再添利器！ nuwacell.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-24 | Nuwacell Biotechnologies Co., Ltd. | 中盛溯源荣登“2025中国医药创新种子企业100强” nuwacell.com ↗ |
| 2025-03-20 | Nuwacell Biotechnologies Co., Ltd. | 喜报！中盛溯源第三款iMSC产品获批临床，GVHD治疗再添利器！ nuwacell.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCR102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06941350 ↗ |